LETTER TO THE EDITOR
IgG4-related lymphadenopathy
Submission date: 2018-01-30
Final revision date: 2018-03-11
Acceptance date: 2018-03-11
Publication date: 2018-04-03
Arch Med Sci Civil Dis 2018;3(1):21-25
TOPICS
REFERENCES (17)
1.
Pieringer H, Parzer I, Wohrer A, Reis P, Oppl B, Zwerina J. IgG4-related disease: an orphan disease with many faces. Orphanet J Rare Dis 2014; 9: 110.
2.
Fernandez-Codina A, Martinez-Valle F, Pinilla B, et al. IgG4-related disease: results from a Multicenter Spanish Registry. Medicine 2015; 94: e1275.
3.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-51.
4.
Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22: 1-14.
5.
Sato Y, Yoshino T. IgG4-Related Lymphadenopathy. Int J Rheumatol 2012; 2012: 572539.
6.
Okazaki K, Umehara H. Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan. Int J Rheumatol 2012; 2012: 357071.
7.
Uchida K, Masamune A, Shimosegawa T, Okazaki K. Prevalence of IgG4-related disease in Japan based on Nationwide Survey in 2009. Int J Rheumatol 2012; 2012: 358371.
8.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteriafor IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology 2012; 22: 21-30.
9.
Cheuk W, Yuen HK, Chu SY, Chiu EK, Lam LK, Chan JK. Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32: 671-81.
10.
Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman disease. Mod Pathol 2009; 22: 589-99.
11.
Takeuchi M, Sato Y, Takata K, et al. Cutaneous multicentric Castleman disease mimicking IgG4-related disease. Pathol Res Pract 2012; 208: 746-9.
12.
Brito-Zeron P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH. Therapeutic approach to IgG4-related disease. Medicine 2016; 95: e4002.
13.
Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015; 67: 1688-99.
14.
Dhobale S, Bedetti C, Killian P, et al. IgG4 related sclerosing disease withmultiple organ involvements and response to corticosteroid treatment. J Clin Rheumatol 2009; 15: 354-7.
15.
Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosisof autoimmune pancreatitis. J Gastroenterol 2014; 49: 961-70.
16.
Yunyun F, Yu C, Panpan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 2017; 7: 6195.
17.
Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 2017; 12: e0183844.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
